Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07HZG
|
|||
| Former ID |
DNC009418
|
|||
| Drug Name |
PF-00734200
|
|||
| Synonyms |
GOSOGLIPTIN; 869490-23-3; UNII-GI718UO477; PF-00734200; PF-734200; CHEMBL515387; GI718UO477; 2-(4-{(3s,5s)-5-[(3,3-Difluoropyrrolidin-1-Yl)carbonyl]pyrrolidin-3-Yl}piperazin-1-Yl)pyrimidine; 869490-47-1; (3,3-difluoropyrrolidin-1-yl)-[(2S,4S)-4-(4-pyrimidin-2-ylpiperazin-1-yl)pyrrolidin-2-yl]methanone; (3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone; (3,3-DIFLUOROPYRROLIDIN-1-YL)[(2S,4S)-4-[4-(PYRIMIDIN-2-YL)PIPERAZIN-1-YL]PYRROLIDIN-2-YL]METHANONE; Gosogliptin [USAN:
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 2 | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H24F2N6O
|
|||
| Canonical SMILES |
C1CN(CC1(F)F)C(=O)C2CC(CN2)N3CCN(CC3)C4=NC=CC=N4
|
|||
| InChI |
1S/C17H24F2N6O/c18-17(19)2-5-25(12-17)15(26)14-10-13(11-22-14)23-6-8-24(9-7-23)16-20-3-1-4-21-16/h1,3-4,13-14,22H,2,5-12H2/t13-,14-/m0/s1
|
|||
| InChIKey |
QWEWGXUTRTXFRF-KBPBESRZSA-N
|
|||
| CAS Number |
CAS 869490-23-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dipeptidyl peptidase 4 (DPP-4) | Target Info | Modulator | [3] |
| KEGG Pathway | Protein digestion and absorption | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7413). | |||
| REF 2 | ClinicalTrials.gov (NCT00473525) 12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin. U.S. National Institutes of Health. | |||
| REF 3 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes.Diabet Med.2011 Apr;28(4):464-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.